This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baughman, A. L.
Right arrow Articles by Lynn, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baughman, A. L.
Right arrow Articles by Lynn, F.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, November 2004, p. 1045-1053, Vol. 11, No. 6
1071-412X/04/$08.00+0     DOI: 10.1128/CDLI.11.6.1045-1053.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Establishment of Diagnostic Cutoff Points for Levels of Serum Antibodies to Pertussis Toxin, Filamentous Hemagglutinin, and Fimbriae in Adolescents and Adults in the United States

Andrew L. Baughman,1* Kristine M. Bisgard,1 Kathryn M. Edwards,2 Dalya Guris,1 Michael D. Decker,3,{dagger} Kathy Holland,2,{ddagger} Bruce D. Meade,4 and Freyja Lynn4

National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia,1 Department of Pediatrics, Division of Infectious Diseases,2 Departments of Preventive Medicine and Medicine (Infectious Diseases), Vanderbilt University School of Medicine, Nashville, Tennessee,3 Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland4

Received 14 May 2004/ Returned for modification 16 July 2004/ Accepted 31 August 2004

Numerous reports have documented that serologic methods are much more sensitive than culture for the diagnosis of pertussis in adolescents and adults. However, a standardized serologic test for pertussis is not routinely available to most clinicians, and the serologic test levels or cutoff points correlated with diseases have not been determined. The goal of the present study was to examine the distribution of immunoglobulin G (IgG) levels against three Bordetella pertussis antigens (pertussis toxin [PT], filamentous hemagglutinin [FHA], and fimbria types 2 and 3 [FIM]) and to determine population-based antibody levels for the purpose of establishing such diagnostic cutoff points. Enzyme-linked immunosorbent assays (ELISAs) were performed with sera from >6,000 U.S. residents aged 6 to 49 years who participated in the Third National Health and Nutrition Examination Survey. Mixture models were developed to identify hypothesized exposure groups and establish diagnostic cutoffs. Quantifiable (>20 ELISA units/ml [EU]) anti-FHA and anti-FIM IgG antibodies were common (65 and 62% of individuals, respectively), but quantifiable anti-PT IgG antibodies were less frequent (16%). Given the distributions of antibody levels, an anti-PT IgG level of ≥94 EU was proposed as the diagnostic cutoff point. Application of this cutoff point to culture-confirmed illness in a prior study investigating cough illness yielded a high diagnostic sensitivity (80%) and specificity (93%). A standardized ELISA for anti-PT IgG with a single serum sample appears to be useful for the identification of recent B. pertussis infection in adolescents and adults with cough illness. The PT cutoff point will be further evaluated in prospective studies of confirmed B. pertussis infection.

* Corresponding author. Mailing address: National Immunization Program, Centers for Disease Control and Prevention, 1600 Clifton Rd., N.E., Mailstop E-61, Atlanta, GA 30333. Phone: (404) 639-8198. Fax: (404) 639-2483. E-mail: dbaughman{at}cdc.gov.

{dagger} Present address: Scientific & Medical Affairs, Aventis Pasteur, Swiftwater, Pa.

{ddagger} Present address: Clinical Trials Office, Vanderbilt-Ingram Cancer Center, Nashville, Tenn.

Clinical and Diagnostic Laboratory Immunology, November 2004, p. 1045-1053, Vol. 11, No. 6
1071-412X/04/$08.00+0     DOI: 10.1128/CDLI.11.6.1045-1053.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Bisgard, K. M., Rhodes, P., Connelly, B. L., Bi, D., Hahn, C., Patrick, S., Glode, M. P., Ehresmann, K. R., and the Pertussis Investigation Team, (2005). Pertussis Vaccine Effectiveness Among Children 6 to 59 Months of Age in the United States, 1998-2001. Pediatrics 116: e285-e294 [Abstract] [Full Text]  
  • Dworkin, M. S. (2005). Adults Are Whooping, but Are Internists Listening?. ANN INTERN MED 142: 832-835 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»